Tenecteplase versus alteplase (TENVALT): A study comparing two thrombolytic agents in acute ischemic stroke

被引:0
|
作者
Sundar, Kaushik [1 ]
Bhirud, Lomesh [1 ]
Panwar, Ajay [1 ]
Cherian, Jerin Jose [2 ]
Paul, Eldho Mathew [3 ]
Kuruttukulam, Gigy Varkey [1 ]
机构
[1] Rajagiri Hosp, Dept Intervent Neurol, Kochi, Kerala, India
[2] Indian Council Med Res, Delhi, India
[3] Rajagiri Hosp, Dept Pharmacol, Kochi, Kerala, India
关键词
Alteplase; tenecteplase; stroke; thrombolysis; efficacy; safety; OPEN-LABEL;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background & Objective: The Indian data comparing the efficacy and safety outcomes of tenecteplase and alteplase in acute ischemic stroke is scarce. We aimed to compare the outcomes of two agents in an Indian population. Methods: TENVALT study was a single centre, retrospective study. Patients aged 18 years or older with acute ischemic stroke were included in this study if they presented within 3 hours of symptom onset and had a deficit with National Institute of Health Stroke Scale (NIHSS) score > 4, had a modified Rankin score (mRS) of 2 or less before the stroke onset and had no evidence of hemorrhage on non-contrast computed tomography of brain. A good functional recovery (mRS score of 0-2) at the end of three months was defined as the primary efficacy outcome. The development of symptomatic intracerebral hemorrhage was considered as the primary safety outcome. Results: A total of 120 patients (alteplase, n=65; tenecteplase, n=55) underwent stroke thrombolysis during this study. The mean age of the presentation in tenecteplase group was 66.6 years and in alteplase group was 62.5 years. Most of the study subjects were males in both the groups (tenecteplase, 78.2%; alteplase, 61.5%). Hypertension was the most common comorbidity in both the groups (tenecteplase, 67.3%; alteplase, 76.9%). Median mRS score at 3 months of follow up was 2 in tenecteplase and 1 in alteplase group; however, the difference between the total number of patients having good functional recovery (mRS 0-2) in the two groups was not statistically significant (tenecteplase 74.5 vs alteplase 87.7%, P=0.09). The total number of patients who had symptomatic intracranial hemorrhage was comparable between the two groups (tenecteplase, 5.5%; alteplase, 6.2%). Conclusion: Tenecteplase appears to be an efficacious alternative to alteplase for stroke thrombolysis and may be better suited to developing countries considering its low cost and ease of administration.
引用
收藏
页码:203 / 208
页数:6
相关论文
共 50 条
  • [1] Tenecteplase versus Alteplase for Acute Ischemic Stroke
    Gonzalez, R. Gilberto
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (03): : 275 - 276
  • [2] Tenecteplase versus Alteplase for Acute Ischemic Stroke REPLY
    Parsons, Mark
    Levi, Christopher
    Davis, Stephen
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (03): : 276 - 276
  • [3] TENECTEPLASE VERSUS ALTEPLASE FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE
    Nakajima, Steven
    Smith, Raymond
    CRITICAL CARE MEDICINE, 2023, 51 (01) : 267 - 267
  • [4] Navigating the Shift: Comparing Safety and Cost of Tenecteplase versus Alteplase in Acute Ischemic Stroke
    Cassano, Carina
    Schiller, Daryl
    Fulman, Magda
    NEUROHOSPITALIST, 2025,
  • [5] A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke
    Parsons, Mark
    Spratt, Neil
    Bivard, Andrew
    Campbell, Bruce
    Chung, Kong
    Miteff, Ferdinand
    O'Brien, Bill
    Bladin, Christopher
    McElduff, Patrick
    Allen, Chris
    Bateman, Grant
    Donnan, Geoffrey
    Davis, Stephen
    Levi, Christopher
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (12): : 1099 - 1107
  • [6] MAJOR BLEEDING OF TENECTEPLASE VERSUS ALTEPLASE IN ACUTE ISCHEMIC STROKE
    Walton, Mary
    Hamilton, Leslie
    Kennedy, Sonia
    Wiseman, Brian
    Rowe, Shaun
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 398 - 398
  • [7] Biosimilar tenecteplase versus alteplase in acute ischemic stroke: A real world study
    Mohan, Ayush
    Komakula, Snigdha
    Murali, Suhas
    Anand, Pooja
    Shah, Dyuti
    Vishnu, V.
    Pandit, Awadh
    Agarwal, Ayush
    Vibha, Deepti
    Singh, Mamta
    Srivastava, M. Padma
    Bhatia, Rohit
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2023, 26 (01) : 54 - 58
  • [8] Tenecteplase versus alteplase after acute ischemic stroke at high age
    Thommessen, Bente
    Naess, Halvor
    Logallo, Nicola
    Kvistad, Christopher E.
    Waje-Andreassen, Ulrike
    Ihle-Hansen, Hege
    Ihle-Hansen, Hakon
    Thomassen, Lars
    Ronning, Ole Morten
    INTERNATIONAL JOURNAL OF STROKE, 2021, 16 (03) : 295 - 299
  • [9] Major Bleeding Postadministration of Tenecteplase Versus Alteplase in Acute Ischemic Stroke
    Walton, Mary N.
    Hamilton, Leslie A.
    Salyer, Sonia
    Wiseman, Brian F.
    Forster, Ann M.
    Rowe, A. Shaun
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (05) : 535 - 543
  • [10] Cost-effectiveness of tenecteplase versus alteplase for acute ischemic stroke
    Nguyen, Chi Phuong
    Lahr, Maarten M. H.
    van der Zee, Durk-Jouke
    van Voorst, Henk
    Roos, Yvo B. W. E. M.
    Uyttenboogaart, Maarten
    Buskens, Erik
    CONTRAST Consortium
    EUROPEAN STROKE JOURNAL, 2023, 8 (03) : 638 - 646